Emerging Therapies for Eosinophilic Esophagitis

Overview

Journal J Allergy Clin Immunol

Specialty Allergy & Immunology

Date 2019 Nov 10

PMID 31705907

Citations 30

Authors

Thomas Greuter

Ikuo Hirano

Evan S Dellon

Affiliations

Soon will be listed here.

Abstract

Despite advances in the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single agent has been approved by the US Food and Drug Administration to treat EoE. Off-label, EoE is currently treated by using the 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endoscopic dilation. In the recent past, considerable progress in terms of EoE treatment has been made: (1) new EoE-specific steroid formulations optimizing mucosal deposition have been developed, which has culminated in recent approval of a budesonide effervescent tablet in Europe; (2) biologics used for other T2-mediated diseases, such as allergic asthma and atopic eczema, as well as purpose-developed biologics, have been studied in phase II trials in patients with EoE; and (3) novel dietary restriction strategies have evolved. Finally, further insights into the pathogenesis of EoE have revealed several novel disease mediators that might be targeted in the future. In the following article we will discuss recent advances in EoE treatment with regard to swallowed topical steroids, biological agents, dietary approaches, and novel molecular targets.

Citing Articles

[Eosinophilic esophagitis].

Greuter T Inn Med (Heidelb). 2025; 66(2):156-164.

PMID: 39792264 DOI: 10.1007/s00108-024-01828-7.

Off-Label Use of Monoclonal Antibodies for Eosinophilic Esophagitis in Humans: A Scoping Review.

Yang B, Li W, Gao Y, Zhang B, Zuo W Biomedicines. 2024; 12(11).

PMID: 39595142 PMC: 11592289. DOI: 10.3390/biomedicines12112576.

A retrospective real-world study on the safety and efficacy of budesonide orodispersible tablets for the induction therapy of eosinophilic oesophagitis.

Geow R, Arena G, Siah C, Picardo S Therap Adv Gastroenterol. 2024; 17:17562848241290346.

PMID: 39421000 PMC: 11483688. DOI: 10.1177/17562848241290346.

Examining the Role of Type 2 Inflammation in Eosinophilic Esophagitis.

Chehade M, Falk G, Aceves S, Lee J, Mehta V, Leung J Gastro Hep Adv. 2024; 1(5):720-732.

PMID: 39131849 PMC: 11307682. DOI: 10.1016/j.gastha.2022.05.004.

Patient-reported symptoms and burden of eosinophilic esophagitis: evidence from real-world clinical practice.

Xu X, Kwiatek J, Siddall J, Genofre E, Stirnadel-Farrant H, Katial R BMC Gastroenterol. 2024; 24(1):246.

PMID: 39097693 PMC: 11297626. DOI: 10.1186/s12876-024-03334-4.

References

Lucendo A, Miehlke S, Schlag C, Vieth M, von Arnim U, Molina-Infante J . Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial. Gastroenterology. 2019; 157(1):74-86.e15. DOI: 10.1053/j.gastro.2019.03.025. View

Greuter T, Safroneeva E, Bussmann C, Biedermann L, Vavricka S, Katzka D . Maintenance Treatment Of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-up Period In Adult Patients. Clin Gastroenterol Hepatol. 2018; 17(3):419-428.e6. DOI: 10.1016/j.cgh.2018.05.045. View

Dellon E, Woosley J, Arrington A, McGee S, Covington J, Moist S . Rapid Recurrence of Eosinophilic Esophagitis Activity After Successful Treatment in the Observation Phase of a Randomized, Double-Blind, Double-Dummy Trial. Clin Gastroenterol Hepatol. 2019; 18(7):1483-1492.e2. PMC: 7058486. DOI: 10.1016/j.cgh.2019.08.050. View

Katzka D, Tadi R, Smyrk T, Katarya E, Sharma A, Geno D . Effects of topical steroids on tight junction proteins and spongiosis in esophageal epithelia of patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014; 12(11):1824-9.e1. DOI: 10.1016/j.cgh.2014.02.039. View

Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel H . Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology. 2010; 139(5):1526-37, 1537.e1. DOI: 10.1053/j.gastro.2010.07.048. View

Dellon E, Katzka D, Collins M, Hamdani M, Gupta S, Hirano I . Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. Gastroenterology. 2016; 152(4):776-786.e5. DOI: 10.1053/j.gastro.2016.11.021. View

Hardenberg J, Braun A, Schon M . A Yin and Yang in Epithelial Immunology: The Roles of the α(CD103)β Integrin in T Cells. J Invest Dermatol. 2017; 138(1):23-31. DOI: 10.1016/j.jid.2017.05.026. View

Miehlke S, Hruz P, Vieth M, Bussmann C, von Arnim U, Bajbouj M . A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut. 2015; 65(3):390-9. PMC: 4789829. DOI: 10.1136/gutjnl-2014-308815. View

de Rooij W, Dellon E, Parker C, Feagan B, Jairath V, Ma C . Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review. Drugs. 2019; 79(13):1419-1434. DOI: 10.1007/s40265-019-01173-2. View

10.

Butz B, Wen T, Gleich G, Furuta G, Spergel J, King E . Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology. 2014; 147(2):324-33.e5. PMC: 4107112. DOI: 10.1053/j.gastro.2014.04.019. View

11.

Hirano I, Collins M, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer A . RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Gastroenterology. 2018; 156(3):592-603.e10. DOI: 10.1053/j.gastro.2018.10.051. View

12.

Greuter T, Alexander J, Straumann A, Katzka D . Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis- Current Concepts and Perspectives for Steroid Use. Clin Transl Gastroenterol. 2019; 9(12):e212. PMC: 6303250. DOI: 10.1038/s41424-018-0074-8. View

13.

Nhu Q, Chiao H, Moawad F, Bao F, Konijeti G . The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation. Am J Gastroenterol. 2018; 113(8):1261-1263. DOI: 10.1038/s41395-018-0145-1. View

14.

Markowitz J, Jobe L, Miller M, Frost C, Laney Z, Eke R . Safety and Efficacy of Reslizumab for Children and Adolescents With Eosinophilic Esophagitis Treated for 9 Years. J Pediatr Gastroenterol Nutr. 2017; 66(6):893-897. DOI: 10.1097/MPG.0000000000001840. View

15.

Noti M, Tait Wojno E, Kim B, Siracusa M, Giacomin P, Nair M . Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nat Med. 2013; 19(8):1005-13. PMC: 3951204. DOI: 10.1038/nm.3281. View

16.

Spergel J, Rothenberg M, Collins M, Furuta G, Markowitz J, Fuchs 3rd G . Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2011; 129(2):456-63, 463.e1-3. DOI: 10.1016/j.jaci.2011.11.044. View

17.

Cheng K, Gupta S, Kantor S, Kuhl J, Aceves S, Bonis P . Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Transl Sci Rare Dis. 2018; 2(3-4):141-155. PMC: 5757645. DOI: 10.3233/TRD-170016. View

18.

Travers J, Rochman M, Miracle C, Cohen J, Rothenberg M . Linking impaired skin barrier function to esophageal allergic inflammation via IL-33. J Allergy Clin Immunol. 2016; 138(5):1381-1383. PMC: 5335915. DOI: 10.1016/j.jaci.2016.09.001. View

19.

Youngblood B, Brock E, Leung J, Falahati R, Bochner B, Rasmussen H . Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis. JCI Insight. 2019; 4(19). PMC: 6795394. DOI: 10.1172/jci.insight.126219. View

20.

Sherrill J, Gao P, Stucke E, Blanchard C, Collins M, Putnam P . Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol. 2010; 126(1):160-5.e3. PMC: 2904342. DOI: 10.1016/j.jaci.2010.04.037. View